Antimicrobial Peptides: a New Frontier in Antifungal Therapy

ABSTRACT Invasive fungal infections in humans are generally associated with high mortality, making the choice of antifungal drug crucial for the outcome of the patient. The limited spectrum of antifungals available and the development of drug resistance represent the main concerns for the current an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Giuseppe Buda De Cesare, Shane A. Cristy, Danielle A. Garsin, Michael C. Lorenz
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2020
Materias:	antifungal drugs antimicrobial peptides mycology Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/1b0d9590b03b46139acd6c7901d2bde6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1b0d9590b03b46139acd6c7901d2bde6
record_format	dspace
spelling	oai:doaj.org-article:1b0d9590b03b46139acd6c7901d2bde62021-11-15T15:55:44ZAntimicrobial Peptides: a New Frontier in Antifungal Therapy10.1128/mBio.02123-202150-7511https://doaj.org/article/1b0d9590b03b46139acd6c7901d2bde62020-12-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.02123-20https://doaj.org/toc/2150-7511ABSTRACT Invasive fungal infections in humans are generally associated with high mortality, making the choice of antifungal drug crucial for the outcome of the patient. The limited spectrum of antifungals available and the development of drug resistance represent the main concerns for the current antifungal treatments, requiring alternative strategies. Antimicrobial peptides (AMPs), expressed in several organisms and used as first-line defenses against microbial infections, have emerged as potential candidates for developing new antifungal therapies, characterized by negligible host toxicity and low resistance rates. Most of the current literature focuses on peptides with antibacterial activity, but there are fewer studies of their antifungal properties. This review focuses on AMPs with antifungal effects, including their in vitro and in vivo activities, with the biological repercussions on the fungal cells, when known. The classification of the peptides is based on their mode of action: although the majority of AMPs exert their activity through the interaction with membranes, other mechanisms have been identified, including cell wall inhibition and nucleic acid binding. In addition, antifungal compounds with unknown modes of action are also described. The elucidation of such mechanisms can be useful to identify novel drug targets and, possibly, to serve as the templates for the synthesis of new antimicrobial compounds with increased activity and reduced host toxicity.Giuseppe Buda De CesareShane A. CristyDanielle A. GarsinMichael C. LorenzAmerican Society for Microbiologyarticleantifungal drugsantimicrobial peptidesmycologyMicrobiologyQR1-502ENmBio, Vol 11, Iss 6 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	antifungal drugs antimicrobial peptides mycology Microbiology QR1-502
spellingShingle	antifungal drugs antimicrobial peptides mycology Microbiology QR1-502 Giuseppe Buda De Cesare Shane A. Cristy Danielle A. Garsin Michael C. Lorenz Antimicrobial Peptides: a New Frontier in Antifungal Therapy
description	ABSTRACT Invasive fungal infections in humans are generally associated with high mortality, making the choice of antifungal drug crucial for the outcome of the patient. The limited spectrum of antifungals available and the development of drug resistance represent the main concerns for the current antifungal treatments, requiring alternative strategies. Antimicrobial peptides (AMPs), expressed in several organisms and used as first-line defenses against microbial infections, have emerged as potential candidates for developing new antifungal therapies, characterized by negligible host toxicity and low resistance rates. Most of the current literature focuses on peptides with antibacterial activity, but there are fewer studies of their antifungal properties. This review focuses on AMPs with antifungal effects, including their in vitro and in vivo activities, with the biological repercussions on the fungal cells, when known. The classification of the peptides is based on their mode of action: although the majority of AMPs exert their activity through the interaction with membranes, other mechanisms have been identified, including cell wall inhibition and nucleic acid binding. In addition, antifungal compounds with unknown modes of action are also described. The elucidation of such mechanisms can be useful to identify novel drug targets and, possibly, to serve as the templates for the synthesis of new antimicrobial compounds with increased activity and reduced host toxicity.
format	article
author	Giuseppe Buda De Cesare Shane A. Cristy Danielle A. Garsin Michael C. Lorenz
author_facet	Giuseppe Buda De Cesare Shane A. Cristy Danielle A. Garsin Michael C. Lorenz
author_sort	Giuseppe Buda De Cesare
title	Antimicrobial Peptides: a New Frontier in Antifungal Therapy
title_short	Antimicrobial Peptides: a New Frontier in Antifungal Therapy
title_full	Antimicrobial Peptides: a New Frontier in Antifungal Therapy
title_fullStr	Antimicrobial Peptides: a New Frontier in Antifungal Therapy
title_full_unstemmed	Antimicrobial Peptides: a New Frontier in Antifungal Therapy
title_sort	antimicrobial peptides: a new frontier in antifungal therapy
publisher	American Society for Microbiology
publishDate	2020
url	https://doaj.org/article/1b0d9590b03b46139acd6c7901d2bde6
work_keys_str_mv	AT giuseppebudadecesare antimicrobialpeptidesanewfrontierinantifungaltherapy AT shaneacristy antimicrobialpeptidesanewfrontierinantifungaltherapy AT danielleagarsin antimicrobialpeptidesanewfrontierinantifungaltherapy AT michaelclorenz antimicrobialpeptidesanewfrontierinantifungaltherapy
_version_	1718427138237923328

Antimicrobial Peptides: a New Frontier in Antifungal Therapy

Ejemplares similares